This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.
Jared  Gollob net worth and biography

Jared Gollob Biography and Net Worth

Jared Gollob is Chief Medical Officer at Kymera Therapeutics. Dr. Gollob is formerly Vice President of Clinical Development and Global Vice President of Medical Affairs at Alnylam Pharmaceuticals.

At Alnylam, Dr. Gollob led early and late stage clinical programs in infectious disease, oncology, and amyloidosis, which resulted in the first proof of concept for RNA interference therapeutics in humans, and culminated in the FDA and EMA approvals of ONPATTRO™ for the treatment of hereditary transthyretin amyloidosis. Prior to joining Alnylam, Dr. Gollob held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. Dr. Gollob has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. He received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

What is Jared Gollob's net worth?

The estimated net worth of Jared Gollob is at least $3.13 million as of February 9th, 2024. Dr. Gollob owns 74,709 shares of Kymera Therapeutics stock worth more than $3,125,825 as of February 23rd. This net worth approximation does not reflect any other investments that Dr. Gollob may own. Additionally, Dr. Gollob receives a salary of $637,810.00 as Insider at Kymera Therapeutics. Learn More about Jared Gollob's net worth.

How old is Jared Gollob?

Dr. Gollob is currently 59 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. The oldest executive at Kymera Therapeutics is Ms. Ellen V. Chiniara Esq., J.D., Chief Legal Officer & Corporate Secretary, who is 65 years old. Learn More on Jared Gollob's age.

What is Jared Gollob's salary?

As the Insider of Kymera Therapeutics, Inc., Dr. Gollob earns $637,810.00 per year. The highest earning executive at Kymera Therapeutics is Dr. Nello Mainolfi M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $975,200.00 per year. Learn More on Jared Gollob's salary.

How do I contact Jared Gollob?

The corporate mailing address for Dr. Gollob and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Jared Gollob's contact information.

Has Jared Gollob been buying or selling shares of Kymera Therapeutics?

In the last ninety days, Jared Gollob has sold $1,637,863.50 of Kymera Therapeutics stock. Most recently, Jared Gollob sold 46,137 shares of the business's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $35.50, for a transaction totalling $1,637,863.50. Following the completion of the sale, the insider now directly owns 74,709 shares of the company's stock, valued at $2,652,169.50. Learn More on Jared Gollob's trading history.

Who are Kymera Therapeutics' active insiders?

Kymera Therapeutics' insider roster includes Bruce Booth (Director), Richard Chesworth (Insider), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.

Are insiders buying or selling shares of Kymera Therapeutics?

In the last twelve months, Kymera Therapeutics insiders bought shares 1 times. They purchased a total of 216,406 shares worth more than $2,518,965.84. In the last twelve months, insiders at the sold shares 5 times. They sold a total of 65,187 shares worth more than $2,226,468.85. The most recent insider tranaction occured on February, 21st when Director Jeffrey W. Albers sold 4,385 shares worth more than $171,234.25. Insiders at Kymera Therapeutics own 16.7% of the company. Learn More about insider trades at Kymera Therapeutics.

Information on this page was last updated on 2/21/2024.

Jared Gollob Insider Trading History at Kymera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2024Sell46,137$35.50$1,637,863.5074,709View SEC Filing Icon  
11/2/2021Sell14,996$63.22$948,047.12View SEC Filing Icon  
3/15/2021Sell10,305$60.17$620,051.8549,747View SEC Filing Icon  
3/11/2021Sell4,695$60.05$281,934.7549,747View SEC Filing Icon  
2/19/2021Sell8,887$55.09$489,584.8399,997View SEC Filing Icon  
2/17/2021Sell7,550$58.39$440,844.5099,997View SEC Filing Icon  
See Full Table

Jared Gollob Buying and Selling Activity at Kymera Therapeutics

This chart shows Jared Gollob's buying and selling at Kymera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kymera Therapeutics Company Overview

Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $41.84
Low: $40.03
High: $42.15

50 Day Range

MA: $30.71
Low: $22.90
High: $41.84

2 Week Range

Now: $41.84
Low: $9.60
High: $42.68


700,005 shs

Average Volume

859,524 shs

Market Capitalization

$2.48 billion

P/E Ratio


Dividend Yield



This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.